Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Recent approval of tolebrutinib in the EU for secondary progressive MS without relapses

Anthony Traboulsee • 28 Jun 2026
EAN 2026
Multiple Sclerosis and Related Disorders BTK inhibitors Tolebrutinib

Anthony Traboulsee, MD, University of British Columbia, Vancouver, Canada, reflects on the recent approval of tolebrutinib in the EU for secondary progressive multiple sclerosis (MS) without relapses. Prof. Traboulsee highlights that this approval addresses the unmet need of treating or slowing down progression. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anthony Traboulsee

Tolebrutinib and disability by MRI activity: post-hoc analysis of HERCULES and GEMINI
1:07
Tolebrutinib and disability by MRI activity: post-hoc analysis of HERCULES and GEMINI
Anthony Traboulsee • 28 Jun 2026
Tolebrutinib reduces new MRI lesions in highly active relapsing MS
2:28
Tolebrutinib reduces new MRI lesions in highly active relapsing MS
Anthony Traboulsee • 9 Apr 2021
Phase III trials of tolebrutinib in relapsing-remitting and progressive MS
2:20
Phase III trials of tolebrutinib in relapsing-remitting and progressive MS
Anthony Traboulsee • 9 Apr 2021
MOG antibody seropositivity in a multi-ethnic population
3:21
MOG antibody seropositivity in a multi-ethnic population
Anthony Traboulsee • 9 Apr 2021

Related Videos

Tolebrutinib and disability by MRI activity: post-hoc analysis of HERCULES and GEMINI
1:07
Tolebrutinib and disability by MRI activity: post-hoc analysis of HERCULES and GEMINI
Anthony Traboulsee • 28 Jun 2026
What is currently known about broad rim lesions in multiple sclerosis?
1:19
What is currently known about broad rim lesions in multiple sclerosis?
Joost Smolders • 27 Jun 2026
The potential value of broad rim lesions in the understanding and management of multiple sclerosis
1:02
The potential value of broad rim lesions in the understanding and management of multiple sclerosis
Joost Smolders • 27 Jun 2026
Exploring the genetic architecture of restless legs syndrome
3:38
Exploring the genetic architecture of restless legs syndrome
Arthur Walters • 17 Jun 2026
The content of VJNeurology is intended for healthcare professionals